NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Not Applicable
Recruiting
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Behavioral: Advance Care Planning conversations
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 222
- Registration Number
- NCT05605574
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 2
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT05600894
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
- Conditions
- Hematologic MalignancyPre-MalignancyPancreatic CancerSolid TumorsGastrointestinal CancerLiver CancerMelanomaLung Cancer
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1200
- Registration Number
- NCT05600933
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Recruiting
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1000
- Registration Number
- NCT05588154
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 350
- Registration Number
- NCT05588128
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT05588141
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
Phase 2
Withdrawn
- Conditions
- Bladder CarcinomaMuscle Invasive Bladder CarcinomaRenal Pelvis and Ureter Urothelial CarcinomaStage IVA Bladder Cancer AJCC v8Urothelial CarcinomaBladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage III Bladder Cancer AJCC v8
- Interventions
- Biological: AtezolizumabProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: CystoscopyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05564416
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2
Recruiting
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionOther: Best PracticeProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Bone Marrow AspirationProcedure: Biopsy ProcedureProcedure: Mutation Carrier ScreeningProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanDrug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: Placebo AdministrationRadiation: Total-Body Irradiation
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2000
- Registration Number
- NCT05564390
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract CarcinomaAdvanced Gallbladder CarcinomaAdvanced Intrahepatic CholangiocarcinomaRecurrent Biliary Tract CarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Hilar Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05564403
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan, United States
🇺🇸Trinity Health Medical Center - Brighton, Brighton, Michigan, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2
Recruiting
- Conditions
- Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmMetastatic HER2-Negative Breast CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone ScanProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Mutation Carrier ScreeningProcedure: Positron Emission TomographyProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇵🇷
Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
🇵🇷PROncology, San Juan, Puerto Rico
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath